Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neisseria meningitidis serogroup W135 is a subgroup of *Neisseria meningitidis* characterized by its specific capsular polysaccharide. It is a Gram-negative, encapsulated diplococcus found in the family Neisseriaceae. W135 is distinguished by molecular typing and is part of the clonal complex ST-11, responsible for significant global outbreaks, including a well-known epidemic during the Hajj in 2000[2][5][8]. This serogroup is a leading cause of invasive meningococcal disease, presenting primarily as meningitis and sepsis, and is associated with high mortality and morbidity worldwide[3][7][9]. Surveillance and vaccination programs are critical for management due to its rapid disease progression and potential for antibiotic resistance[1][5][9].
Bactericidal inhibition of cell wall synthesis (β-lactams: penicillins, cephalosporins) Blockage of nucleic acid synthesis (rifampin, ciprofloxacin) Immunization-induced antibody production (vaccine)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neisseria meningitidis serogroup W135 (N. meningitidis W135).